Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

1,435 total articles

Piper Sandler Cuts Qorvo Price Target to $90, Citing Faster-than-Expected Android Business Resizing

Piper Sandler Cuts Qorvo Price Target to $90, Citing Faster-than-Expected Android Business Resizing

Piper Sandler has lowered its 12-month price target for Qorvo Inc to $90 from $110 while maintaining a Neutral rating. The firm pointed to disappointing March quarter guidance and a faster-than-expected downsizing of Qorvo's lower-tier Android business as the primary drivers of the adjustment. Data in the company's filings and analyst reports under…

Piper Sandler Lifts Pinnacle Financial Partners Target to $122, Citing Loan Growth and Balance Sheet Expansion

Piper Sandler Lifts Pinnacle Financial Partners Target to $122, Citing Loan Growth and Balance Sheet Expansion

Piper Sandler raised its price target for Pinnacle Financial Partners (PNFP) to $122 from $120 and kept an Overweight rating after reviewing the bank's fourth-quarter 2025 results and 2026 guidance. The firm boosted 2026 and 2027 EPS estimates, pointing to stronger loan growth and a larger balance sheet as the rationale. Pinnacle reported a revenue…

Piper Sandler Lifts Praxis Precision Medicines Price Target to $1,200 While Maintaining Overweight

Piper Sandler Lifts Praxis Precision Medicines Price Target to $1,200 While Maintaining Overweight

Piper Sandler hiked its price target on Praxis Precision Medicines (PRAX) to $1,200 from $450 and reaffirmed an Overweight rating. The firm updated its model to include four programs and projects substantial peak U.S. sales by 2046, while Praxis prepares New Drug Applications for two lead candidates by mid-February 2026 and has completed a priced p…

KeyBanc Stands by Overweight Call on UnitedHealth as Medicare Advantage Rate Debate Pressures Shares

KeyBanc Stands by Overweight Call on UnitedHealth as Medicare Advantage Rate Debate Pressures Shares

KeyBanc Capital Markets has reaffirmed an Overweight rating and a $400 price target on UnitedHealth Group (UNH), arguing the shares are priced below their fundamental value despite investor concern over proposed Medicare Advantage rates for 2027. The company reported a stronger-than-expected medical loss ratio in the fourth quarter and offered 2026…

Bernstein Sticks With Outperform on Boeing After Strong Q4 Showing

Bernstein Sticks With Outperform on Boeing After Strong Q4 Showing

Bernstein SocGen Group maintained an Outperform rating and a $298.00 price target on Boeing following the company’s fourth-quarter results. The target implies about 22% upside from the prevailing share price of $244.56, though InvestingPro’s Fair Value model flags the stock as potentially overvalued. The quarter featured materially stronger-than-ex…